|
Congestive heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The gene expression pattern of GRK2 and β2-adrenoceptor as molecular markers of cardiac dysfunction was altered in patients with severe PR compared with controls and was similar to expression in patients with advanced HF.
|
30104167 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Heart failure leads to altered β2-adrenoceptor/cyclic adenosine monophosphate dynamics in the sarcolemmal phospholemman/Na,K ATPase microdomain.
|
30165515 |
2019 |
|
Congestive heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We propose that the molecular switch for the loss of transverse tubules in HF and their restoration following tadalafil treatment involves the BAR domain protein Amphiphysin II (BIN1) and the restoration of catecholamine sensitivity is through reductions in G-protein receptor kinase 2, protein phosphatase 1 and protein phosphatase 2 A abundance following phosphodiesterase 5 inhibition.
|
31043634 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
β2-adrenergic receptor autoantibodies alleviated myocardial damage induced by β1-adrenergic receptor autoantibodies in heart failure.
|
29746700 |
2018 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure.
|
30374408 |
2018 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The present study shows that the Gln27Gln genotype of β2-AR is the most predominant while the Glu27Glu is the least prevalent in our HF population.
|
28933308 |
2018 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, the functional consequences of structural changes upon β2AR-cAMP signalling during progression from hypertrophy to advanced HF are unknown.
|
28505272 |
2017 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
After controlling for demographics, functional status, and treatment adherence, polymorphisms in ADRB1, ADRB2 and eNOS are associated with healthcare outcomes in heart failure patients.
|
22543981 |
2012 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
|
22760495 |
2012 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our data show that enhanced β(2)AR phosphorylation by GRK, in addition to PKA, leads the receptor to G(i)-biased signaling, which, in turn, contributes to the pathogenesis of heart failure, marking G(i)-biased β(2)AR signaling as a primary event linking upregulation of GRK to cardiac maladaptive remodeling, failure and cardiodepression.
|
22179058 |
2012 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether a predefined combination of the Arg389Gly polymorphism in the adrenergic β(1) -receptor gene (ADRB1) and the Gln27Glu polymorphism in the adrenergic β(2) -receptor gene (ADRB2) could predict survival in carvedilol- and metoprolol-treated chronic heart failure (HF) patients.
|
21395649 |
2011 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
RGD |
Thus, the redistribution of beta(2)ARs in heart failure changes compartmentation of cAMP and might contribute to the failing myocardial phenotype.
|
20185685 |
2010 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A total of 226 patients with end-stage HF (ejection fraction ≤35%) were genotyped for the two β(1)AR SNPs and the three β(2)AR SNPs.
|
20803192 |
2010 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Beta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly in patients with heart failure.
|
19886995 |
2009 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We investigated the clinical response of chronic heart failure patients with beta(2)-adrenergic receptor Gln(27)-->Glu polymorphism treated for 6 months with carvedilol, a alpha/beta-antagonist with antioxidant properties.The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism.
|
19422106 |
2009 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
RGD |
Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor.
|
19587314 |
2009 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Numerous studies have demonstrated that beta(1)- and beta(2)-adrenergic receptor gene (ADRB1 and ADRB2) variants influence cardiovascular risk and beta-blocker responses in hypertension and heart failure.
|
18615004 |
2008 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Moreover, the Arg16Gln27 beta-2 AR haplotype might have some predictive value for poor outcome of heart failure.
|
17916379 |
2008 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Allelic variants at codons 16 and 27 of the beta(2)-adrenergic receptor gene (ADRB2) have shown clinical and pharmacological implications in asthma, hypertension, ischemic heart failure, diabetes, obesity, and cystic fibrosis.
|
18440968 |
2008 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
There are many findings about the changes of beta(1)- and beta(2)-AR in heart failure (HF).
|
19120134 |
2008 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
At present it appears to be clear that, for cardiovascular diseases such as hypertension, coronary artery disease and chronic heart failure, beta(1)- and beta(2)-AR polymorphisms do not play a role as disease-causing genes; however, they might affect drug responses.
|
18353108 |
2008 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure.
|
17223428 |
2007 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine the influence of common polymorphisms of the ADRB2 on cardiovascular structure and function in patients with CHF.
|
17336757 |
2007 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that genetic variation of the ADRB2 is associated with differences in PF in CHF patients but not in healthy subjects, which may be related to an increased susceptibility of the homozygous Arg subjects to agonist-mediated desensitization of ADRB2s in the lungs, or related to an influence of this polymorphism on cardiac diastolic properties.
|
17099033 |
2006 |
|
Congestive heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Thus, the role of the Thr164Ile-beta(2)AR in CHF remains questionable.
|
16783489 |
2006 |